Herein, we highlight that tumor‐intrinsic SETD2 deficiency reshapes the immunosuppressive TME via neutrophils in pancreatic tumorigenesis, potentially providing a therapeutic strategy for pancreatic cancer patients with SETD2 deficiency. This evidence concerns the gene SETD2 and familial pancreatic carcinoma.